Seeking Alpha

Dr. John Faessel's  Instablog

Dr. John Faessel
Send Message
Dr. John L. Faessel is a seasoned and respected Wall Street professional with industry-wide recognition for expertise in market strategy and analysis. He is widely recognized for his insights in public companies. For over 20-years Dr. Faessel’s ON THE MARKET reports have been widely distributed... More
  • Star Scientific - Powerful New Peer Reviewed Science Shows Anatabine Inhibits Inflammation In The Central Nervous System 0 comments
    Feb 21, 2013 11:02 AM

    Dr. John L. Faessel

    ON THE MARKET

    Commentary and Insights

    Powerful new peer reviewed science shows anatabine inhibits inflammation in the central nervous system

    Update: Star Scientific (STSI) Nasdaq

    Before we go on - take 85 seconds to see why there is all the interest in anatabine

    No anatabine: http://www.youtube.com/watch?v=nZ4sL-VgW7Q

    With anatabine: http://www.youtube.com/watch?v=yt2DKp36-oo

    This above mentioned peer review published on 1/30/2013 (see here) follows the research that the Roskamp Institute released on 5/8/2012 (see here.)

    The study results showed that the anatabine dietary supplementation resulted in a dramatic reduction in the rate of paralysis of hind limbs of mice using a standard mouse model of multiple sclerosis [MS]. In addition to the better motor performance of the mice, there was evidence of suppression of the normal inflammatory response that accompanies neuronal destruction in this model.

    The very recent peer reviewed abstract validates the Roskamp Institutes research and therefore suggest that anatabine inhibits pro-inflammatory Th1 and Th17 cytokines which are known to play critical roles in the induction and severity of MS and Experimental Autoimmune Encephalomyelitis [EAE].

    The full title of the 26 page peer review is, "Amelioration of Experimental Autoimmune Encephalomyelitis by Anatabine," and can be viewed here.

    Noteworthy excerpts from the abstract:

    · Found that orally administered anatabine markedly suppressed neurological deficits associated with EAE.

    · Revealed that anatabine significantly reduced Th1 and Th17 cytokines known to contribute to the development of EAE.

    · Anatabine appears to significantly suppress STAT3 and p65 NFκB phosphorylation in the spleen and the brain of EAE mice.

    · Found that anatabine alleviated the infiltration of macrophages/microglia and astrogliosis and significantly prevented demyelination in the spinal cord of EAE mice

    These two transcription factors regulate a large array of inflammatory genes including cytokines suggesting a mechanism by which anatabine antagonizes pro-inflammatory cytokine production.

    The mice used in this testing were vaccinated to induce a severe inflammatory process in the brain, which has the effect of destroying neurons and causing progressive paralysis. The disease model looks very similar to that which occurs in human multiple sclerosis.

    While we know in the hierarchy of scientific investigations that animal studies do not carry the weight of human studies there is an approximate 80% correlation. Interesting for example is that 99% of mouse genes have an equivalent in humans making mice ideal for studying. Intriguing from the above link; "More so than any other genetically tractable organism, the mouse offers a close glimpse of humankind in terms of similarity in the underlying physiology, tissue structure and organization." The 2007 Nobel Prize in Physiology and Medicine was awarded to Mario Capecchi, Sir Martin Evans and Oliver Smithies for their pioneering work on gene targeting in the mouse.

    From a 2011 Mayo Clinic & Cleveland Clinic study - [that] "it is "overwhelmingly likely" that MS is fundamentally an inflammatory disease, and not a neurodegenerative Alzheimer-like disease." Published in the December 8, 2011, issue of the New England Journal of Medicine. Link here.

    Multiple sclerosis [MS] is a chronic inflammatory demyelinating autoimmune disorder of the central nervous system [CNS]. Clinical symptoms of MS not only include motor disabilities but also cognitive deficits [1] and increasing evidence indicates that axonal and neuronal injury are present both in the white and grey matter areas emphasizing a degenerative disease course [2], [3]. A variety of drugs are now approved for the treatment of MS. All of these drugs have potentially serious side effects and can suffer response failure during prolonged treatment [4], [5]. There is therefore a significant need to develop novel and safer medications to treat MS.

    And a final take away… How do we help people?

    When you read that "anatabine" reverses demyelination of the spinal cord, reduces inflammation and sees significant paralysis reduction, and it is completely safe and one can buy anatabine / Anatabloc at GNC or online? If I had MS, I certainly would want to know about it.

    MS is a cruel disease. It hits people when they are young and is difficult to diagnose early-on. Some are greatly affected, becoming severely disabled - while other can peruse relatively normal lives. For many it has fatal consequences.

    If you know anyone who has MS; copy the peer review study, copy the Star press release, show them the striking YouTube videos above - get it to them, their doctor, caregivers etc... No safety issues or side effects... Help save a life…

    Disclaimer; I bought shares of Star Scientific in the open market and have no relationship with the company.

Back To Dr. John Faessel's Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (0)
Track new comments
Be the first to comment
Full index of posts »
Latest Followers
Posts by Themes
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.